Unicorns On Paper Are Nice. But Billion Dollar Exits From San Diego Are Real.
Featuring Faheem Hasnain.
Mr. Hasnain has served as Receptos President, CEO and a director since November 2010. Prior to joining Receptos, he was the President and CEO and a director of Facet Biotech Corporation, a biology driven antibody company with a focus in multiple sclerosis and oncology. He held that position from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010. Previously, Mr. Hasnain was President, CEO and a director of PDL BioPharma, Inc. from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008, Mr. Hasnain served at Biogen Idec Inc., a biotechnology company specializing in neurological disorders, autoimmune disorders and cancer.
With Pratik Shah, Ph.D., who brings more than 15 years of entrepreneurial and leadership experience in the biopharma industry. He is also a partner in the venture capital firm Thomas, McNerney & Partners. Dr. Shah previously worked at various biotech companies after serving at McKinsey & Company where he focused on biotechnology and venture capital projects. Dr. Shah is a board member of Cebix, Ocera Therapeutics, and SG Biofuels.
And Carin Canale as the moderator. Ms. Canale is Founder and CEO of Canale Communications, a public and investor relations firm focused exclusively on life science companies.
Wednesday, October 28, 2015 | 5:30 p.m.
Johnson & Johnson Innovation, JLabs – 3210 Merryfield Row, San Diego, CA 92121
FREE to members | $50 non-members